Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Silence Therapeutics has reported revenues of £716,090 for the six months ended 30 June 2010, compared to £856,626 for the comparable period in 2009.
Subscribe to our email newsletter
The company has posted a operating loss of £6.91m the six months ended 2010, compared to operating loss of £3.61m, for the comparable period in 2009.
Silence Therapeutics has reported net loss for the half-year as £7.05m before taxation (six months to 30 June 2009: £3.57m; full year 2009: £7.51m).
Silence Therapeutics CEO Phil Haworth said that 2010 has been a pivotal year for Silence Therapeutics.
“Our new, more comprehensive structure has facilitated multiple advances in the three areas that we believe will be most critical in the coming years – partnerships, intellectual property and clinical progress, Haworth said.
“We are delighted by our progress in the first half of 2010 and look forward to continued success during the second half of 2010.”
Silence Therapeutics is a biotechnology company engaged in the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases.